Hepatitis

2017 Hepatitis A Outbreaks Tied to Drug Use, Homelessness

2017 Hepatitis A Outbreaks Tied to Drug Use, Homelessness

Investigations of hepatitis A outbreaks in four states in 2017 suggested a shift toward increasing person-to-person transmission of hepatitis A.

Over Two Million People Living With Hep C From 2013 to 2016

Over Two Million People Living With Hep C From 2013 to 2016

During 2013 to 2016, more than two million people in the United States had current hepatitis C virus infection.

First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong

First Human Case of Rat Strain of Hepatitis E Seen in Hong Kong

Hepatitis E infection identified in 56-year-old man who had received a liver transplant in May 2017.

Authorized Generics of Epclusa, Harvoni Will Soon Be Available for HCV Treatment

Authorized Generics of Epclusa, Harvoni Will Soon Be Available for HCV Treatment

By

The list price for the generics is $24,000 for the most common course of therapy.

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Lenvatinib Approved as First-Line Treatment for Unresectable Hepatocellular Carcinoma

The approval was supported by findings from the multicenter, randomized, open-label, noninferiority trial, REFLECT (N=945), which included patients with previously untreated, metastatic or unresectable HCC.

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Good Outcomes for HCV-Negative Recipients of HCV Kidneys

Hepatitis C virus-negative recipients of HCV-infected kidneys experience HCV cure and good quality of life.

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

Mulpleta Approved for Thrombocytopenia in Patients With Chronic Liver Disease

By

The FDA has approved Mulpleta for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hep B Core Antibody-Positive Organs May Provide Solutions to the Organ Donor Crisis

Hepatitis B core Antibody (anti-HB c+) organs may be a safe and ethical transplant option in an era where increased medical knowledge has enabled greater treatment for hepatitis.

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

WHO Targets for Chronic Hepatitis B Will Be Cost-Effective

Meeting World Health Organization targets for chronic hepatitis B by 2030 will be cost-effective.

NFID Initiative Working to Up Hepatitis B Vaccination Rates

NFID Initiative Working to Up Hepatitis B Vaccination Rates

A new initiative to increase hepatitis B virus vaccination rates among at-risk adults has been developed.

Canada Updates Guidelines for Hepatitis C Virus Infection

Canada Updates Guidelines for Hepatitis C Virus Infection

The Canadian Medical Association provided an updated evidence-based recommendations for the treatment of patients with chronic hepatitis C virus.

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

Novel Hepatitis B Virus Treatment Gets FDA's Fast Track Designation

By

The FDA has granted Fast Track designation to a novel antiviral in development for the treatment of HBV infection.

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

Blood-Brain Barrier Damage, Psychiatric Impairment in HCV Infection and Alcohol Abuse

By

Alcohol use disorder in patients with HCV infection is associated with increased symptoms of depression and anxiety compared with patients with HCV and no history of alcohol abuse.

Universal Screening Best Strategy for Hepatitis C in France

Universal Screening Best Strategy for Hepatitis C in France

Universal screening is the most effective strategy for hepatitis C virus in France.

Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma

Keytruda sBLA Granted Priority Review for Advanced Hepatocellular Carcinoma

By

The sBLA is based on results from the Phase 2 KEYNOTE-224 trial, which enrolled 104 individuals with advanced hepatocellular carcinoma previously treated with sorafenib who were either intolerant to or showed progression of disease after treatment.

Transplanting HCV-Infected Kidneys Into HCV-Infected Patients Increased Adjusted Life Expectancy

Transplanting HCV-Infected Kidneys Into HCV-Infected Patients Increased Adjusted Life Expectancy

For patients with HCV infection with end-stage renal disease, transplant of an HCV-infected kidney followed by treatment is more cost-effective than transplant of an HCV-uninfected kidney.

Multidose Hepatitis Vaccine Adherence in US Adults May Be Suboptimal

Multidose Hepatitis Vaccine Adherence in US Adults May Be Suboptimal

By

Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.

Long-Term Safety Data for Tenofovir Alafenamide in Chronic Hepatitis B Added to Labeling

Long-Term Safety Data for Tenofovir Alafenamide in Chronic Hepatitis B Added to Labeling

By

Vemlidy, a nucleoside analogue (reverse transcriptase inhibitor), is currently approved to treat chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.

Project ECHO: Educational Support to Improve Hepatitis Care

Project ECHO: Educational Support to Improve Hepatitis Care

By

Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.

Demographic Insights Into Hepatitis Vaccination Practices

Demographic Insights Into Hepatitis Vaccination Practices

By

From 2007 to 2015, the majority of initial hepatitis A, B, and A/B vaccinations were administered by primary care providers.

Hepatitis B Vaccines Compared in Older Adults With Type 2 Diabetes

Hepatitis B Vaccines Compared in Older Adults With Type 2 Diabetes

By

For the analysis, study authors looked at data specifically for patients with type 2 diabetes aged 60 to 70 years.

Direct-Acting Antivirals Effective for Hepatitis C in Seniors

Direct-Acting Antivirals Effective for Hepatitis C in Seniors

For older patients with hepatitis C virus, direct-acting antiviral therapy is effective.

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

Normal on-Treatment ALT Linked to Reduced Hepatic Events in Hepatitis B

By

Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.

Risk for Liver Cirrhosis in Methorexate-Treated Psoriasis With Chronic Viral Hepatitis

Risk for Liver Cirrhosis in Methorexate-Treated Psoriasis With Chronic Viral Hepatitis

By

Real-world data have demonstrated no rise in the development of incident liver cirrhosis among patients with psoriasis and either CHB or CHC who have received long-term MTX therapy.

Post-Transplant HCV Treatment Increases Access to Kidney Transplantation

Post-Transplant HCV Treatment Increases Access to Kidney Transplantation

Post-transplant hepatitis C treatment increases access to transplant and reduces waitlist time among hepatitis C-positive patients awaiting kidney transplantation.

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

CDC Issues Updated Advisory Regarding Outbreaks of Hepatitis A

By

Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

By

The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.

HCV Guidelines Updated to Include Recommendations for Key Populations

HCV Guidelines Updated to Include Recommendations for Key Populations

By

The guidelines were developed by the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America.

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

Novel Medicaid Strategy Proposed to Increase Access to HCV Treatment

By

A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.

Two Hepatitis C Virus Infection Treatments to Be Discontinued

Two Hepatitis C Virus Infection Treatments to Be Discontinued

By

The discontinuation is voluntary and is not related to product quality, safety or efficacy.

Sign Up for Free e-newsletters